On physical examination, she was minimally alert and jaundiced with a fixed right pupil. There was no overt bleeding. Brain computed tomography (CT) showed a large 2.6-cm-diameter subdural hematoma with 2 cm of leftward midline shift ( Figure 1A She continued to be minimally responsive, with persistent oozing at the surgical site. Repeat head CT showed an increase in the size of the subdural hematoma. Plasma fibrinogen remained low, at 100 mg/dL, despite appropriate transfusion support. On hospital day 6, D-dimer was checked due to concern for hyperfibrinolysis, and was extremely elevated, at 37 890 ng/mL D-dimer units (DDUs).
Kaolin-activated thromboelastography showed normal R time (reaction time: time from start of the test to initial fibrin formation), normal K time (time from initial clot formation to an amplitude of 20 mm), normal alpha angle (slope between R and K, indicating rate of clot formation and fibrin crosslinking), normal Ly-30 (amplitude at 30 minutes measuring fibrinolysis), and a decrease in maximum amplitude (representing overall stability of the clot) at 27.30 mm.
The thromboelastography assay was performed following aggressive transfusion support, possibly reducing the sensitivity of the assay to detect a hemostatic or fibrinolytic abnormality. In response, on hospital day 7, TXA was started with a 2 mg/kg bolus intravenously, and continuous infusion at 200 mg/h. D-dimer decreased to 13 221 ng/mL DDU within 24 hours, and transfusion requirements decreased as depicted in Figure 2 . On hospital day 8, the patient was extubated and transferred to the medical floor. TXA was decreased to 100 mg/h continuously on day 14. As imaging and D-dimer stabilized, neurologic status also improved. On hospital day 15, intravenous TXA was converted to oral dosing by starting 1300 mg of oral TXA and discontinuing the infusion 2 hours later. This was followed by administration of 1300 mg of TXA orally every 6 hours with intent to taper the dose following D-dimer. On hospital day 16, the dosing frequency was reduced to every 8 hours, but D-dimer increased from 5000 to 9900 ng/mL DDU within 12 hours, and the fibrinogen Secondary hyperfibrinolysis in liver disease occurs in the setting of DIC. 5 Several assays have been developed to detect hyperfibrinolysis, including the euglobulin clot lysis time, dilute whole blood clot lysis time, turbidimetric plasma clot lysis assay, global fibrinolytic capacity in the whole blood, and thromboelastography. However, none of these assays are sensitive enough to detect hyperfibrinolysis in
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. , PRBC; , platelets; , FFP; , Cryo; , fibrinogen; , D-dimer Table 1 shows a summary of reports in which antifibrinolytics were used in cirrhosis-related bleeding.
Tranexamic acid is a synthetic lysine analogue and mimics lysine residues on fibrin, to which plasminogen normally binds. 19, 20 It prevents fibrinolysis by binding to plasminogen, preventing its conversion to plasmin. It can directly inhibit plasmin activity at higher doses. 10 TXA was also shown to attenuate the inflammatory response in trauma patients with survival benefit. 12 There is no general consensus on the dosing of TXA for hyperfibrinolysis in cirrhosis. It can be given as an intravenous (i.v.) bolus (20-25 mg/kg) followed by continuous infusion at 1-2 mg/kg/h or 1 g over 10 minutes followed by 1 g over 8 hours. 10 We chose to give an i.v. bolus, then a continuous infusion at 2 mg/kg/h. The D-dimer markedly decreased within a day of infusion, there were no thrombosis complications, and the clinical course improved (Figure 2 ). Risk of thrombosis in patients with DIC and hyperfibrinolysis receiving TXA should be considered, as enhanced coagulation activity from DIC compounded by shutdown of the fibrinolytic pathway from TXA can increase the risk for thrombus formation. 21 However, there are very limited data on TXA and increased risk for thrombosis in patients with hematologic disorders. 20 Thus, it is reasonable to consider administration of TXA in a patient with life-threatening bleeding. 22 and mortality in similar cases. Earlier identification in this case might have shortened the hospitalization.
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